ArticleJournal of molecular modeling2025
Ultrafast terahertz-induced torque disruption of fentanyl's μ-opioid receptor binding for precision overdose reversal.
Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resonant terahertz-induced stark field disruption of fentanyl's μ-opioid receptor binding for precision overdose reversal.Journal of molecular modeling · 2026Article
- Quantum-topological simulation of Berry phase-induced fentanyl-μ-opioid receptor dissociation via terahertz vortex fields.Journal of molecular modeling · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThis study establishes a quantum-biophysical framework for non-invasive opioid overdose reversal by demonstrating ultrafast terahertz (THz) torque-mediated disruption of fentanyl-μ-opioid receptor (μOR) binding. By targeting the vibrational modes of the fentanyl-μOR complex with resonant THz pulses (1-1.5 THz, ≥ 100 kV/cm), the study examines two key binding configurations: the Asp147 salt bridge (D147) and His297 hydrogen bond (H297). The model reveals that THz-induced torque reduces the dissociation barrier by 3.2-3.8 kcal/mol through mechanical disruption of the N-H⁺···O⁻ interaction, achieving 50% unbinding within 1.2 ps at optimal frequencies. The H297 configuration dissociates 40% faster than D147, indicating a pharmacologically preferable site for intervention. A sigmoidal dose-response is observed in the 100-150 kV/cm range, enabling > 90% dissociation efficacy under non-thermal conditions. These findings offer a novel electromagnetic approach for modulating opioid pharmacodynamics and inform the development of receptor-targeted antidotes via precision bioelectromagnetic strategies. While this study demonstrates the theoretical feasibility of THz-induced dissociation, future experimental work is needed to address translational challenges such as tissue penetration and biological specificity.
methodsThe study employs a quantum-classical hybrid framework combining time-dependent Schrödinger equation simulations with classical electrodynamics. Fentanyl is modeled as a confined asymmetric rotor interacting with a µOR-like potential landscape under circularly polarized THz radiation. Quantum torque is derived from angular momentum operators coupled to the electric field vector. Site-specific binding configurations (D147 and H297) are simulated with field-driven vibrational excitation and potential energy surface deformation. Dissociation dynamics and barrier modulation are quantified using Fermi's Golden Rule and time-evolved wavepacket propagation. Numerical computations were performed in Wolfram Mathematica 13.1, with molecular input parameters validated against DFT-based dipole moments, mass tensors, and force-field data extracted from experimental literature.
Indexed as
Identifiers
40728567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.